Oxurion NV (OXUR) | Stock Overview & Key Data
Oxurion NV | Small-cap | Healthcare
Oxurion NV | Small-cap | Healthcare
Oxurion NV Performance Comparison
Stock Range
Today's Range
Low: €0.03
High: €0.03
on August 8, 2025
52 Week Range
Low: €0.02
High: €2.00
on July 21, 2025
on May 29, 2024
All-Time High: €478,200.00 on January 7, 2013
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Market Cap
€1.5M
EPS
0.00
P/E Ratio (TTM)
0.00
Forward P/E
-0.06
P/B Ratio
N/A
PEG Ratio
-0.06
Div. Yield
N/A
ROE
-1.08%
Beta
0.504
Debt to Equity
-1.02
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
134,650.00%
Profit Margin
3,966.67%
Returns and Earnings
Return on Assets (TTM)
3.90%
Return on Equity (TTM)
-1.08%
EBITDA
€402.0K
Net Income (TTM)
€119.0K
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.00
Quarterly Revenue Growth (YoY)
-97.60%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Oxurion NV OXUR | 1.52M Small-cap | 0.00% | 0.00% | -57.14% | -87.50% | -88.00% | -97.00% | -100.00% | -100.00% |
| Argenx SE ARGX | 36.23B Large-cap | -3.13% | 23.59% | 5.46% | -8.89% | -5.73% | 18.28% | 57.28% | 191.69% |
| UCB S.A UCB | 35.08B Large-cap | -3.12% | 8.59% | 17.93% | -2.51% | -3.58% | 15.99% | 149.93% | 78.52% |
| European Medical ALEMS | 19.47M Small-cap | -2.13% | 4.55% | -16.36% | -26.98% | -23.33% | -37.75% | -89.95% | -92.27% |
| Celyad Oncology S.A CYAD | 16.16M Small-cap | -2.50% | 11.43% | -17.02% | -9.30% | -41.79% | 69.57% | -80.98% | -95.52% |
| Biosenic SA BIOS | 1.63M Small-cap | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -80.00% | -98.25% | -99.73% |
Ownership & Short Interest
Insider Ownership
3.66%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
7M
Average 90-Day Volume
3M
Oxurion NV Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Oxurion NV would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is OXUR's 52-week high and low?
- In the last 52 weeks, Oxurion NV reached a high of €2.00 (on May 29, 2024) and a low of €0.02 (on July 21, 2025).
- What is the market cap and P/E ratio for OXUR?
- Curious about Oxurion NV's size and valuation? Its market capitalization stands at 1.52M. When it comes to valuation, the P/E ratio (trailing twelve months) is 0.00, and the forward P/E (looking ahead) is -0.06.
- Does OXUR pay dividends? If so, what's the yield?
- As for dividends, Oxurion NV isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Oxurion NV's main competitors or similar companies to consider before investing?
When looking at Oxurion NV, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Argenx SE
ARGX36.23B Healthcare Biotechnology 18.28% 57.28% UCB S.A
UCB35.08B Healthcare Biotechnology 15.99% 149.93% European Medical
ALEMS19.47M Healthcare Biotechnology -37.75% -89.95% Celyad Oncology S.A
CYAD16.16M Healthcare Biotechnology 69.57% -80.98% Biosenic SA
BIOS1.63M Healthcare Biotechnology -80.00% -98.25% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Oxurion NV? (e.g., ROE, Debt/Equity)
- To get a sense of Oxurion NV's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -1.08%, the Debt to Equity ratio from the most recent quarter is -1.02, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for OXUR?
- Looking at Oxurion NV's growth, its revenue over the trailing twelve months (TTM) was €3K. Compared to the same quarter last year (YoY), quarterly revenue grew by -97.60%, and quarterly earnings saw a YoY growth of N/A.
- How much of OXUR stock is held by insiders and institutions?
- Wondering who owns Oxurion NV stock? Company insiders (like executives and directors) hold about 3.66% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.